Industry Overview

France prostate cancer diagnosis & treatment market was valued at $476.5 million in 2025 and is projected to reach $959.6 million by 2035, growing at a CAGR of 7.3% during the forecast period (2026-2035). The market is growing due to the increasing incidence of prostate cancer, particularly among the aging male population. Rising awareness regarding early screening through prostate-specific antigen testing and digital rectal examination is contributing to higher diagnosis rates. Continuous advancements in diagnostic technologies and imaging accuracy are improving early detection and risk stratification. Expanding availability of advanced therapeutic options, including immunotherapy and targeted therapy, is enhancing treatment outcomes and patient survival. In addition, supportive reimbursement frameworks and strengthening oncology infrastructure across emerging and developed economies are reinforcing sustained market expansion.

Market Dynamics

Epidemiological and Demographic Expansion

The French Prostate Cancer Diagnostic and Therapeutic Market is advancing on account of a steady rise in diagnosed cases, particularly among men above 60 years of age. The demographic shift toward an older population has intensified the demand for sustained screening, monitoring, and long-term disease management. Greater clinical emphasis on early-stage identification has improved patient inflow into diagnostic pathways. Structured national cancer programs have strengthened referral networks across public and private healthcare institutions. These factors are collectively reinforcing procedural volumes across diagnostic imaging and laboratory testing services.

Therapeutic Innovation and Healthcare Investment

Market progression is further supported by the introduction of advanced hormonal agents, targeted radioligand therapies, and precision-based treatment protocols. Regulatory endorsements for innovative therapeutics have broadened physician confidence in adopting next-generation modalities. Hospital investments in nuclear medicine infrastructure and molecular imaging platforms are expanding treatment capacity. Favorable reimbursement mechanisms within the French healthcare system are improving patient access to high-cost therapies. Continuous clinical research activity within academic centers is sustaining innovation and long-term market momentum.

Market Segmentation

• Based on diagnostic technique, the market is segmented into prostate-specific antigen test and digital rectal exam.
• Based on therapy, the market is segmented into hormonal therapy, chemotherapy, immunotherapy, radiation therapy, and targeted therapy.

Precision Staging: PSMA-PET Imaging Uptake

PSMA-targeted PET imaging is the fastest-growing diagnostic subsegment in France, driven by recent national approvals and rapid hospital adoption. Regulatory clearances and radiotracer launches have expanded clinical use for staging and biochemical recurrence. Greater sensitivity versus conventional imaging is prompting earlier use in treatment planning and clinical trials. Key industrial contributors include Telix Pharmaceuticals and major imaging platform providers deploying scanner-capacity and tracer distribution networks. Payer interest and center-level investments are improving access outside tertiary hospitals. Expect continued volume growth as validated tracers and hybrid PET/MR workflows scale in referral centers.

Targeted Strike: PSMA Radioligand Therapy Momentum

PSMA-directed radioligand therapy is the leading fast-growing therapeutic subsegment, expanding from late-line to earlier treatment settings after pivotal approvals. Demonstrated improvements in progression-free and overall survival have accelerated clinician uptake and trial enrollment. The commercial anchor in Europe is Novartis, following marketing authorization and label expansions for PSMA-targeted lutetium therapies. Ongoing studies, combination strategies (with androgen-directed agents), and growing manufacturing capacity are the main adoption drivers. Health-system budget planning and specialized nuclear-medicine infrastructure remain the principal short-term constraints.

Market Players Outlook

The major companies operating in the France prostate cancer diagnostic and therapeutic market include Astellas Pharma Inc., Pfizer Inc., Johnson & Johnson, Novartis AG, F. Hoffmann-La Roche AG, among others. Market players are leveraging partnerships, collaborations, mergers, and acquisition strategies for business expansion and innovative product development to maintain their market positioning.

Recent Developments

• In May 2024, Curium began supplying the first commercial doses of Pylclari (an 18F-PSMA PET tracer) across multiple sites in France. This tracer helps detect prostate-specific membrane antigen-positive lesions for staging and recurrence assessment. Broader availability of Pylclari expands advanced imaging options for prostate cancer management in clinical settings across the country.

The Report Covers

• Market value data analysis of 2025 and forecast to 2035.
• Annualized market revenues ($ million) for each market segment.
• Country-wise analysis of major geographical regions.
• Key companies operating in the France prostate cancer diagnostic and therapeutic market. Based on the availability of data, information related to new products and relevant news is also available in the report.
• Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
• Analysis of market-entry and market expansion strategies.
• Competitive strategies by identifying ‘who-stands-where’ in the market.